Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis.

Abstract

Thirty-nine client-owned dogs with osteoarthritis were treated with 5 mg/kg firocoxib administered orally, once a day for 52 weeks. Veterinary examinations were performed on approximately days 0, 15, 90, 180, 270 and 360. Twenty-five dogs completed the study. The withdrawal rate associated with gastrointestinal side effects was low (5.1 per cent of dogs). Based on the owners' assessment, 82 per cent of the dogs had improved at day 15, 84 per cent of the 32 remaining dogs had improved at day 90, and 96 per cent of the 25 dogs that completed the trial had improved at day 360. During this trial, 12 (48 per cent) of the 25 remaining dogs showed an improvement in their lameness from day 90 to day 360 (P<0.05).

• Authors: A Autefage, F M Palissier, E Asimus, C Pepin-Richard
• Journal: The Veterinary record (Vet Rec) Vol. 168 Issue 23 Pg. 617 (Jun 11 2011) ISSN: 2042-7670 [Electronic] England
• PMID: 21642297 (Publication Type: Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Sulfones
• 4-Butyrolactone
• firocoxib

Topics

• 4-Butyrolactone (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Administration, Oral
• Animals
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects, therapeutic use)
• Dog Diseases (drug therapy, pathology)
• Dogs
• Female
• Lameness, Animal (drug therapy)
• Male
• Osteoarthritis (drug therapy, pathology, veterinary)
• Prospective Studies
• Severity of Illness Index
• Sulfones (administration & dosage, adverse effects, therapeutic use)
• Treatment Outcome